Waiting Time from Diagnosis to Treatment has no Impact on Survival in Patients with Esophageal Cancer

Annals of Surgical Oncology

Volumn 23, Issue 8, 2016, Pages 2679-2689

  Visser, E ^a   Leeftink, A G ^a,b   van Rossum, P S N ^a   Siesling, S ^b,c   van Hillegersberg, R ^a   Ruurda, J P ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF TWENTE   (Netherlands)

^c Department of Research   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18;

ADJUVANT CHEMORADIOTHERAPY; ADULT; ARTICLE; CANCER SURGERY; CANCER SURVIVAL; DISEASE FREE SURVIVAL; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NEOADJUVANT THERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; ADENOCARCINOMA; ESOPHAGUS TUMOR; MIDDLE AGED; MORTALITY; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TIME TO TREATMENT; TREATMENT OUTCOME;

ADENOCARCINOMA; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; SURVIVAL RATE; TIME-TO-TREATMENT; TREATMENT OUTCOME;

EID: 84961616418     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-016-5191-6     Document Type: Article

References (37)

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.
2. Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. Lancet. 2013;381:400–12.
3. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–20.
4. van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074–84.
5. Shapiro J, van Lanschot JJ, Hulshof MC, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16:1090–8.
6. van der Sluis PC, Ubink I, van der Horst S, et al. Safety, efficacy, and long-term follow-up evaluation of perioperative epirubicin, Cisplatin, and capecitabine chemotherapy in esophageal resection for adenocarcinoma. Ann Surg Oncol. 2015;22:1555–63.
7. Jaarrapportage Dutch Surgical Clinical Audit, DICA rapportage 2014. http://www.clinicalaudit.nl/jaarrapportage/2014/. Accessed 8 Sept 2015.
8. Dutch Cancer Society. Advies inzake wachttijdnormen in de kankerzorg. Amsterdam: Signaleringscommissie Kanker, Werkgroep: ‘Wachtlijstproblematiek, specifiek gericht op de patient met kanker’. 2006.
9. VWS, Ministerie van Volksgezondheid, Welzijn en Sport. Brief Nieuwe wachttijdenregistratie; 30 mei. 2008.
10. Cimprich B. Pretreatment symptom distress in women newly diagnosed with breast cancer. Cancer Nurs. 1999;22:185–94.
11. Mor V, Allen S, Malin M. The psychosocial impact of cancer on older versus younger patients and their families. Cancer. 1994;74:2118–27.
12. Visser MR, van Lanschot JJ, van der Velden J, Kloek JJ, Gouma DJ, Sprangers MA. Quality of life in newly diagnosed cancer patients waiting for surgery is seriously impaired. J Surg Oncol. 2006;93:571–7.
13. Wang J, Liu F, Gao H, et al. The symptom-to-treatment delay and stage at the time of treatment in cancer of esophagus. Jpn J Clin Oncol. 2008;38:87–91.
14. Rothwell JF, Feehan E, Reid I, Walsh TN, Hennessy TP. Delay in treatment for oesophageal cancer. Br J Surg. 1997;84:690–3.
15. Witzig R, Schonberger B, Fink U, et al. Delays in diagnosis and therapy of gastric cancer and esophageal adenocarcinoma. Endoscopy. 2006;38:1122–6.
16. Martin IG, Young S, Sue-Ling H, Johnston D. Delays in the diagnosis of oesophagogastric cancer: a consecutive case series. BMJ. 1997;314:467–70.
17. Kotz BS, Croft S, Ferry DR. Do delays between diagnosis and surgery in resectable oesophageal cancer affect survival? A study based on West Midlands cancer registration data. Br J Cancer. 2006;95:835–40.
18. Grotenhuis BA, van Hagen P, Wijnhoven BP, Spaander MC, Tilanus HW, van Lanschot JJ. Delay in diagnostic workup and treatment of esophageal cancer. J Gastrointest Surg. 2010;14:476–83.
19. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471–74.
20. Verhage RJ, Zandvoort HJ, ten Kate FJ, van Hillegersberg R. How to define a positive circumferential resection margin in T3 adenocarcinoma of the esophagus. Am J Surg Pathol. 2011;35:919–26.
21. Blom RL, Lagarde SM, van Oudenaarde K, et al. Survival after recurrent esophageal carcinoma has not improved over the past 18 years. Ann Surg Oncol. 2013;20:2693–8.
22. Parry K, Visser E, van Rossum PS, Mohammad NH, Ruurda JP, van Hillegersberg R. Prognosis and treatment after diagnosis of recurrent esophageal carcinoma following esophagectomy with curative intent. Ann Surg Oncol. 2015;22 Suppl 3:1292–300.
23. Richards MA, Westcombe AM, Love SB, Littlejohns P, Ramirez AJ. Influence of delay on survival in patients with breast cancer: a systematic review. Lancet. 1999;353:1119–26.
24. Smith EC, Ziogas A, Anton-Culver H. Delay in surgical treatment and survival after breast cancer diagnosis in young women by race/ethnicity. JAMA Surg. 2013;148:516–23.
25. Torring ML, Frydenberg M, Hansen RP, Olesen F, Vedsted P. Evidence of increasing mortality with longer diagnostic intervals for five common cancers: a cohort study in primary care. Eur J Cancer. 2013;49:2187–98.
26. Gonzalez-Barcala FJ, Garcia-Prim JM, Alvarez-Dobano JM, et al. Effect of delays on survival in patients with lung cancer. Clin Transl Oncol. 2010;12:836–42.
27. Yun YH, Kim YA, Min YH, et al. The influence of hospital volume and surgical treatment delay on long-term survival after cancer surgery. Ann Oncol. 2012;23:2731–7.
28. McLean SR, Karsanji D, Wilson J, et al. The effect of wait times on oncological outcomes from periampullary adenocarcinomas. J Surg Oncol. 2013;107:853–8.
29. Pruitt SL, Harzke AJ, Davidson NO, Schootman M. Do diagnostic and treatment delays for colorectal cancer increase risk of death? Cancer Causes Control. 2013;24:961–77.
30. Currie AC, Evans J, Smith NJ, Brown G, Abulafi AM, Swift RI. The impact of the two-week wait referral pathway on rectal cancer survival. Colorectal Dis. 2012;14:848–53.
31. Thompson MR, Asiimwe A, Flashman K, Tsavellas G. Is earlier referral and investigation of bowel cancer patients presenting with rectal bleeding associated with better survival? Colorectal Dis. 2011;13:1242–8.
32. Gray RE, Fitch MI, Phillips C, Labrecque M, Klotz L. Presurgery experiences of prostate cancer patients and their spouses. Cancer Pract. 1999;7:130–5.
33. Jones RV, Greenwood B. Breast cancer: causes of patients’ distress identified by qualitative analysis. Br J Gen Pract. 1994;44:370–1.
34. Rapoport Y, Kreitler S, Chaitchik S, Algor R, Weissler K. Psychosocial problems in head-and-neck cancer patients and their change with time since diagnosis. Ann Oncol. 1993;4:69–73.
35. Sneldiagnostiek UMC Utrecht. http://www.umcutrecht.nl/nl/Ziekenhuis/Afdelingen/Cancer-Center/Sneldiagnostiek. Accessed 8 Sept 2015.
36. Ahn S, Cho J, Park CK, Kim S, Kim K. A large cohort of consecutive patients confirmed frequent HER2-positivity in gastric carcinomas with advanced stages. Lab Invest. 2013;93:142A.
37. Hulscher JB, van Sandick JW, de Boer AG, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med. 2002;347:1662–9.